Bordetella pertussis 165-9K/129G, which produces a nontoxic form of pertussis toxin (PT), was used to prepare a whole-cell diphtheria-tetanus-pertussis (DTP) vaccine. The in vivo potency and the serological response induced by this vaccine were comparable to those of the conventional DTP vaccine which contains active PT. The toxic activities induced by PT such as leukocytosis, histamine sensitivity, and potentiation of anaphylactic reactions, which are present in the conventional DTP vaccine, were absent in the new vaccine. These results suggest that the introduction of a whole-cell vaccine containing B. pertussis 165-9K/129G would induce the same immunity as the conventional vaccine and would avoid the administration of a harmful toxin to children.
The cellular vaccine against pertussis, composed of killed Bordetella pertussis cells, was introduced in the 1940s, and since then it has been successfully used to control whooping cough in many countries. Recently, the use of this vaccine has become controversial because of the many side effects that have been associated with pertussis vaccine inoculation. Some of these are mild, such as redness and fever, while others are severe, such as neurological damage and death.
These severe side effects had been previously calculated to occur with a frequency of 1/110,000 and 1/300,000, respectively (11) . Recently, other investigators reexamined the data and concluded that the severe side effects were not due to the vaccine, suggesting that there are no severe side effects associated with pertussis vaccination (2) . Given the low frequency of these events (1/110,000), it is difficult to draw good conclusions, and the question of the severe side effects remains controversial.
One thing that is well known about the cellular vaccine is that it contains a detectable amount of active pertussis toxin (PT), a molecule which in vaccinated children induces proliferation of lymphocytes and hypoglycemia. In animal models, this molecule and the cellular vaccine induce lymphocytosis, sensitization to histamine, potentiation of anaphylaxis, enhancement of insulin secretion, induction of immunoglobulin E (1, 13) , and many other systemic effects. A vaccine devoid of active PT would be preferable and would avoid the inoculation of children with a toxin which is known to cause many harmful effects. However, reports in the literature suggest that active PT is necessary for the potency of the whole-cell vaccine (1, 14) . To overcome the problems associated with pertussis vaccination, acellular vaccines devoid of active PT are being developed and tested in clinical trials. However, it may take a few years before such vaccines are approved for general use, and at least at the beginning, they may not be available for developing countries.
We have developed strains of B. pertussis that produce forms of PT which are nontoxic but maintain all the immunological properties of wild-type PT (17, 18) . These mole-* Corresponding author.
cules are the best candidates available today to be included in acellular pertussis vaccines (19, 20, 20a) .
In this study, we investigated whether the strain of B. pertussis which produces a nontoxic form of PT may also be used to prepare a whole-cell pertussis vaccine. Our results show that active PT is not necessary for the potency of the cellular pertussis vaccine; this suggests that safer cellular vaccines can be developed. Therefore, an improved cellular vaccine may be a good alternative to cover the period required to introduce acellular vaccines.
MATERIALS AND METHODS
Strains and antigens. B. pertussis 165-9K/129G derives from B. pertussis 165, which is routinely used for the Sclavo cellular vaccine. By genetic manipulation, the codons for arginine 9 and glutamic acid 129 have been replaced with codons for lysine and glycine, respectively. Because of these two amino acid substitutions, B. pertussis 165-9K/129G produces a PT antigen which is nontoxic (18) . Both the wild-type strain 165 and the engineered strain 165-9K/129G were grown in a 20-liter fermentor with Stainer-Scholte medium (23) .
Vaccine composition. Bulk purified diphtheria and tetanus toxoids, obtained from routine production batches at Sclavo, were combined with B. pertussis cells to manufacture diphtheria-tetanus-pertussis (DTP) vaccines. Each 0. (10) . The (22) , whereas the presence of active PT in the supernatant was evaluated by a Chinese hamster ovary (CHO) cell assay (7) . To test whether B. pertussis 165-9K/ 129G may undergo spontaneous reversion and produce active PT, we grew the strain in a 100-liter fermentor. At the end of fermentation, the supernatant was tested for the presence of active PT in the CHO cell assay (7) . In addition, the culture was plated in Bordet-Gengou agar, and 20 colonies were taken, grown in liquid medium, and tested for the production of PT by ELISA and CHO cell assay.
ELISAs. The ELISA for detection of PT-9K1129G in the B. pertussis culture supernatant was a modified version of that described by Sato et al. (22) . Briefly, the wells of a flatbottomed polystyrene microtest plate (Dynatech Laboratories, Inc., Alexandria, Va.) were sensitized with 6 ,ug of fetuin (Sigma Chemical Co., St. Louis, Mo.) in 200 ,ll of phosphate-buffered saline (PBS) containing 0.02% NaN3. After incubation at 37°C for 2 h and overnight at 4°C, cells were washed three times with PBS containing 0.05% Tween 20 and 0.02% NaN3 (PTN buffer). Different aliquots (5 to 40 pul) of culture supernatant were then added to the wells.
Plates were incubated for 2 h at 37°C and then washed as previously described. Monoclonal antibody 1B7 to the S1 subunit of PT (21) The ELISA for detection of specific antibodies raised in guinea pigs was performed as previously described (17) . For coating, 1 ,ug of purified antigen (PT, filamentous hemagglutinin [FHA], 69-kDa antigen, or diphtheria and tetanus toxoids) per well was used. Each serum sample was tested in duplicate, and absorbance values were averaged. Immunoglobulin G titers were evaluated, and the serum dilutions were reported on a graph against the average of the respective absorbances. The intercept through the flex point with the axis of absorbances represents the absorbance value of the undiluted serum (ABS-MAX). The average of the ABS-MAX obtained in the group of immunized guinea pigs was then compared after every bleeding with that of preimmune serum. The increase of ABS-MAX is considered statistically significant when it is at least four times higher than the prevaccination value.
Chinese hamster ovary cell assay. The clustering activity of the culture supernatant of B. pertussis 165-9K/129G was detected as described by Hewlett et al. (7) . Briefly, 104 CHO cells were incubated for 48 h with 10-fold dilutions of the supernatant which were previously tested for PT-9K/129G content or wild-type PT (0.3 pg/ml to 90 ng/ml); the minimum clustering dose was determined.
PT neutralization. The method used to evaluate the level of toxin-neutralizing antibodies induced by vaccination was essentially the same as that described elsewhere (5, 17) . Neutralizing titers were expressed as the reciprocal of the highest serum dilution causing complete inhibition of the clustering activity induced by the native toxin.
Diphtheria toxin neutralization (Vero cell assay). The Vero cell test was performed in 96-well microtiter plates (Costar, Cambridge, Mass.) by the method described by Miyamura et al. (12) . Briefly, serum samples from guinea pigs immunized with one or two doses of conventional or engineered wholecell vaccine were twofold diluted directly in the wells in culture medium M199 containing 10% fetal calf serum, 2 mM glutamine, 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid), and 50 pug of gentamicin per ml. The volume of diluted serum added to each well was 20 pl.
Diphtheria toxin (80 LF/ml diluted 1/105) was added to each well in a volume of 20 pLl, and the plates were then incubated for 3 h at 37°C. After the incubation period, 200 pLl of culture medium containing 109 Vero cells was added to each well.
The microtiter plates were then incubated at 37°C in an atmosphere of 5% C02, and after 48 to 72 h, the neutralizing effect of diphtheria toxin activity on Vero cells was detected in a Titertek Multiskan following cell staining. The titer of the toxic effect of diphtheria toxin alone was determined in each plate. The neutralizing titer was expressed as the reciprocal of the highest serum dilution causing complete inhibition of the toxic effect induced by diphtheria toxin.
Leukocytosis-promoting and histamine-sensitizing activity. Leukocytosis was assayed by injecting female BALB/c mice intraperitoneally (i.p.) on day 0 with 0.5 ml of saline alone or with 1, 0.2, or 0.04 human dose of either conventional or engineered DTP cellular vaccine. As a positive control, additional groups of mice were injected i.p. with 2.5, 0.5, or 0.1 p,g of wild-type PT. On day 3, blood samples were drawn at the orbital plexus and leukocytosis was measured in a Coulter Counter (Coulter Electronics, Ltd., Luton, England). Results were expressed as mean ± standard deviation of leukocyte counts from five animals tested individually.
On day 6, the same mice were challenged i.p. with 4 mg of histamine dichlorohydrate (Sigma) in 0.5 ml of saline, and 24 h later, deaths were registered.
Potentiation of anaphylaxis. Induction of anaphylactic sensitivity was evaluated by the method described by Steinman et al. (24) . BALB/c mice (H-2d genotype) were injected i.p. on days 0 and 2 with 0.5 ml of saline alone or 1, 0.2, or 0.04 human dose of either conventional or engineered DTP cellular vaccine. As a positive control, additional groups of mice were injected i.p. with 0.5 ml of saline containing 2.5, 0.5, or 0.1 p,g of wild-type PT. On days -1, 1, and 6, the same mice received i.p. 1 mg of bovine serum albumin (BSA; Sigma) in 0.5 ml of saline. Deaths were recorded 2 h after the last administration of BSA.
Vaccine potency. Antipertussis potency was evaluated by the intracerebral (i.c.) challenge assay according to the World Health Organization recommendations (27 In vivo titers of diphtheria-and tetanus toxin-neutralizing antibodies were evaluated according to the Italian pharmacopoeia in guinea pigs (8) and mice (9), respectively. To detect antidiphtheria titers, we injected groups of self-white Hartley guinea pigs (250 to 300 g) subcutaneously (s.c.) with 0.03, 0.012, and 0.0048 ml of conventional or engineered DTP vaccines. As a positive control, groups of guinea pigs were injected with the same volumes of a European reference preparation for diphtheria toxoid containing 140 IU per ml. Four weeks later, the animals were injected s.c. with 1 ml of a diphtheria toxin containing approximately 100 LD50.
To evaluate the antitetanus titers, we inoculated groups of 16 CD1 mice (17 to 22 g) (Table 2) . Similarly, the engineered DTP, when inoculated i.p., did not stimulate any sensitization of mice to a lethal challenge performed 6 days later with the vasoactive amine histamine. In contrast, 0.2 human dose of the conventional DTP or 0.5 ,ug of wild-type PT per mouse caused 80% deaths in groups of five animals ( Table 2 ). The engineered DTP was unable to potentiate BSA anaphylaxis, a phenomenon which has been associated with pertussis vaccine encephalopathy (26) . In contrast, this pertussis-dependent murine anaphylaxis occurred in 80% of mice given 0.2 human dose of the conventional DTP (Table  2) .
Vaccine potency. We next compared the ability of the engineered DTP with that of the conventional DTP vaccine to protect mice from a lethal i.c. challenge infection with virulent B. pertussis. Mice were immunized i.p. with various amounts of a standard cellular pertussis vaccine as a positive control and various dilutions of either engineered or conventional vaccines. Immunizations were followed 2 weeks later by i.c. challenge with the standard virulent strain B. pertussis 18323. The engineered DTP vaccine induced a dosedependent protection of mice from paralysis with a median protective dose (PD50) of 0.00708 ml per mouse, which was similar to that (0.00739 ml) of the conventional vaccine ( Table 3) . As a consequence, the engineered and the conventional vaccines contained, respectively, 16 and 15 IU/ml (Table 4 ), indicating that the two vaccines had a comparable antipertussis potency. Despite this, the engineered vaccine induced anti-diphtheria toxin and anti-tetanus toxin titers lower than those obtained with the conventional vaccine (Table 4) . However, the lower confidence limits (74 IU/ml for antidiphtheria titer and 212 IU/ml for antitetanus titer), which are the parameters to be considered for protection, were significantly above the minimum requirements of the Italian Pharmacopoeia. Immunogenicity. Groups of five guinea pigs were treated, (Table 5) . A further and comparable increase of the specific ELISA titers could be observed in sera obtained 2 weeks after the booster injection of either vaccines ( Table  5 ). The increase in antibody titers after the first and the second immunizations correlated with the neutralizing activity in the CHO and Vero cell assays. In fact, sera obtained from animals injected with either vaccine showed comparable in vitro neutralizing titers both against PT and diphtheria toxin (Table 5) .
Sera from guinea pigs administered with one or two doses of either vaccine were also tested for their agglutinating titers, expressed as international units per milliliter and as reciprocals of the highest serum dilution, giving a visible agglutination of a suspension of B. pernussis 165 cells. One human dose of both whole-cell vaccines could induce the same level of agglutinins (2.86 IU/ml) ( Table 5) . After a booster injection, the engineered DTP gave an agglutinating titer (11.43 IU/ml) which was higher than that (5.72 IU/ml) induced by the conventional vaccine (Table 5 ). However, this has not been repeated enough times to know whether this is a significant difference. (15, 16) . Based on this, it has been often speculated that the potency of the whole-cell pertussis vaccine is also due to the presence of active PT (1, 14) .
B. pertussis 165-9K/129G, which produces a nontoxic form of PT, enabled us to show in a definitive way that active PT is not needed for the potency of the whole-cell pertussis vaccine. In our experiments, whole-cell DTP vaccines containing either wild-type B. pertussis 165 or the engineered B. pertussis 165-9K/129G, which produces a nontoxic form of PT, have a similar potency in the i.c. challenge assay. Furthermore, they induce comparable responses to PT, FHA, 69-kDa antigen, and the agglutinogens. The finding that the conventional DTP vaccine (containing active PT) and the engineered vaccine (containing nontoxic PT) induce similar responses to many of the antigens of B. pertussis is not in contrast with the adjuvanticity of active PT. In fact, these antigens presented by the whole cells may already give an optimal immune response which cannot be increased by the presence of an adjuvant. Consistent with this observation is the finding that purified antigens such as diphtheria and tetanus toxoid, which need an adjuvant for optimal activity, give a lower response in the vaccine containing a nontoxic form of PT (Table 4) . Fortunately, this is not a problem because the responses to diphtheria and tetanus are well above the minimum titer required to induce protection.
Our findings suggest that a whole-cell DTP vaccine can be developed with a B. pertussis strain which does not contain active PT and that this vaccine could replace the conventional vaccine. The introduction of such a vaccine is not expected to decrease the frequency of local and systemic side effects caused by endotoxin such as redness, swelling, and fever. Nevertheless, it may have obvious advantages. (i) It would avoid the inoculation of children with an active toxin which is known to cause leukocytosis, hypoglycemia, histamine sensitization, and anaphylaxis potentiation; and (ii) it may provide a vaccine devoid of the severe side effects associated with pertussis vaccination. Although the presence of these side effects is still controversial (3, 6, (24) (25) (26) , there is no doubt that inoculation of children with active PT exposes them to several risks. For instance, it is not difficult to imagine that under rare occasions, some of the children that are given DPT vaccine will have been preexposed to an antigen that predisposes them to an anaphylactic reaction and that this can be potentiated by the active PT present in the vaccine. The risk of this anaphylactic reaction, which in the past has been proposed as a model for the neurological damage caused by the cellular pertussis vaccine, is not present with the vaccine described in this report.
In conclusion, the vaccine that we described induces the same immunity as the conventional vaccine and is likely to improve the safety of pertussis vaccination. Therefore, it may be a useful alternative to the conventional vaccine and could be used to cover the period required for the introduction of acellular vaccines.
